MIRA — Mira Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $20.51m
- $17.68m
Annual income statement for Mira Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 0.068 | 2.15 | 7.05 | 8.53 | 8.02 |
| Operating Profit | -0.068 | -2.15 | -7.05 | -8.53 | -8.02 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -0.068 | -2.18 | -7.06 | -12 | -7.85 |
| Net Income After Taxes | -0.068 | -2.18 | -7.06 | -12 | -7.85 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -0.068 | -2.18 | -7.06 | -12 | -7.85 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -0.068 | -2.18 | -7.06 | -12 | -7.85 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.005 | -0.148 | -0.479 | -0.811 | -0.508 |
| Dividends per Share |